Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2022-09-21 | 2022-04-01 |
| Drug Identification Number | 02496127 | 02496127 |
| Brand name | ERTAPENEM FOR INJECTION | ERTAPENEM FOR INJECTION |
| Common or Proper name | Ertapenem for Injection, 1g SD Vial 20mL | Ertapenem for Injection, 1g SD Vial 20mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | ERTAPENEM | ERTAPENEM |
| Strength(s) | 1G | 1G |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 20mL | 20mL |
| ATC code | J01DH | J01DH |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-02-01 | |
| Actual start date | 2022-05-02 | 2022-02-01 |
| Estimated end date | Unknown | 2022-05-02 |
| Actual end date | 2022-09-20 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | On 100% allocation. | Fresenius Kabi Canada regrets to advise that due to increased demand and production delays, we will be placing our Ertapenem for Injection, 1g SD Vial 20mL. on a reduced allocation. Contract customers will be allocated 75% of their historical average monthly volumes effective today, February 1, 2022. Further, we will be facing a backorder on both products beginning March 1, 2022. |
| Health Canada comments |